

**Neuland Laboratories Limited**  
11th floor (5th level), Phoenix IVY Building,  
Plot No.573A-III, Road No.82, Jubilee Hills,  
Hyderabad-500033, Telangana, India.



CONTACT  
040 6761 1600 / 6761 1700  
neuland@neulandlabs.com  
neulandlabs.com

February 9, 2026

To

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai – 400 001

**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Press Release**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing Press Release on the Financial Results of the Company for the quarter and nine months ended December 31, 2025.

The Press Release is also being uploaded on the website of the Company at [www.neulandlabs.com](http://www.neulandlabs.com)

This is for your information and records.

Yours sincerely,  
For **Neuland Laboratories Limited**

**Sarada Bhamidipati**  
**Company Secretary**

*Encl: As above*



## Neuland 9MFY26 Total income at Rs.1264.5 crore; EBITDA at Rs.284 crore

**Hyderabad, India, Feb 9, 2025** – Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the half year ended Dec 31<sup>st</sup>, 2025.

**Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said,** *“The revenues this quarter are in line with the outlook we envisaged for the year, however the product mix within businesses as well as increased operating expenses is reflected in subdued EBITDA margins. We continue to see good momentum in the business which is driving our investments with the long-term in view, ensuring Neuland can take advantage of the number of growth opportunities.”*

**In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added** *“We are seeing increasing interest from a wider range of customers interested in our capabilities as a proven commercial NCE drug substance manufacturer as well as an integral partner in the innovation journey. Our investments are leading to more engagements with existing customers while also attracting new customers who are looking for specific niche capabilities.”*

### Financial Summary

Particulars (Rs Cr)	Rs. crore				
	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)
<b>Total Income</b>	447.8	401.9	11.4%	516.1	-13.2%
<b>EBITDA</b>	85.0	90.3	-5.9%	156.9	-45.8%
<b>EBITDA Margin</b>	19.0%	22.5%	350 bps	30.4%	-1140 bps
<b>Exceptional Item*</b>	-	55.8	-	-	-
<b>Profit Before Tax*</b>	54.3	127.5	-57.4%	129.0	-57.9%
<b>PBT Margin</b>	12.1%	31.7%	-1960 bps	25.0%	-1290 bps
<b>Profit After Tax</b>	40.4	101.4	-60.2%	96.5	-58.1%

## Q3 FY26 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST on Monday, Feb 9, 2025** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

## About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 1000+ Regulatory filings across the US (73 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit [www.NeulandLabs.com](http://www.NeulandLabs.com).

**If you have any questions or require further information, please feel free to contact**

***IR Department at Neuland***

Tel: +91 40 6761 1600

Email: [ir@neulandlabs.com](mailto:ir@neulandlabs.com)

***Ravi Udeshi / Minakshi Machutre***

***EY IR***

Email: [ravi.udeshi@in.ey.com](mailto:ravi.udeshi@in.ey.com) / [Minakshi.machutre@in.ey.com](mailto:Minakshi.machutre@in.ey.com)